Drug Profile

ACP 204

Alternative Names: ACP-204

Latest Information Update: 08 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ACADIA Pharmaceuticals
Class Antidementias; Antipsychotics; Behavioural disorder therapies
Mechanism of Action Serotonin 5-HT2A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase III Psychotic disorders
Phase II Lewy body disease

Most Recent Events

31 Jul 2025 ACADIA Pharmaceuticals plans a phase III trial for Lewy body disease (PO, Capsule) in August 2025 (NCT07095465) (EudraCT2025-521711-39-00)
18 Jul 2025 Phase-II clinical trials in Lewy body disease (In adults, In the elderly) in USA (PO) (NCT07029581)
26 Jun 2025 Preclinical trials in Lewy body disease in USA (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com